North Star Asset Management Inc. Grows Holdings in Illumina, Inc. (NASDAQ:ILMN)

North Star Asset Management Inc. raised its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 6.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 85,604 shares of the life sciences company's stock after purchasing an additional 5,160 shares during the period. North Star Asset Management Inc. owned approximately 0.05% of Illumina worth $11,439,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Golden State Wealth Management LLC purchased a new stake in shares of Illumina in the 4th quarter worth about $32,000. Fourth Dimension Wealth LLC purchased a new position in shares of Illumina during the 4th quarter valued at about $40,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Illumina during the 4th quarter valued at approximately $45,000. Assetmark Inc. increased its holdings in Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. bought a new stake in Illumina during the fourth quarter valued at about $48,000. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ILMN shares. JPMorgan Chase & Co. lowered their price objective on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Piper Sandler lowered their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research report on Thursday, May 15th. Stephens reiterated an "overweight" rating and issued a $105.00 target price on shares of Illumina in a research report on Tuesday, May 20th. Barclays cut their price target on Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research note on Thursday, April 10th. Finally, Morgan Stanley reduced their target price on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $128.15.

Insider Transactions at Illumina

In other news, CFO Ankur Dhingra purchased 6,100 shares of the company's stock in a transaction on Monday, May 12th. The stock was bought at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the purchase, the chief financial officer now directly owns 24,906 shares of the company's stock, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.60% of the company's stock.

Illumina Price Performance

Shares of NASDAQ ILMN traded up $1.94 on Wednesday, hitting $84.43. The company's stock had a trading volume of 2,409,469 shares, compared to its average volume of 2,326,302. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company has a market capitalization of $13.37 billion, a price-to-earnings ratio of -10.99, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. The stock has a 50 day moving average of $78.00 and a 200-day moving average of $107.72. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the previous year, the firm posted $0.98 EPS. Illumina's revenue was down 1.4% on a year-over-year basis. As a group, research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.